CRISPR Therapeutics stays a Hold as CASGEVY launch lags; watch cash burn, revenue delays, and CTX310/CTX611 catalysts for ...
CRISPR Therapeutics AG CRSP on Friday reported its fourth-quarter and full-year 2025 financial results, highlighting continued clinical progress, expanding uptake of Casgevy, and momentum across its ...
The earnings results for CRISPR Therapeutics (NASDAQ: CRSP) for Q4 were made public on Thursday, February 12, 2026 at 04:00 PM. Here's a comprehensive overview of the announcement. CRISPR Therapeutics ...
7d
Assessing CRISPR Therapeutics (CRSP) Valuation After Recent Mixed Trading And Discounted P/B Ratio
CRISPR Therapeutics overview after recent trading moves CRISPR Therapeutics (CRSP) has seen mixed trading recently, with the ...
Precedence Research, a leading strategic research firm, today released a comprehensive overview of the gene therapy and ...
CRISPR-Cas 9 is a gene-editing tool that made it possible to rewrite any organism's genetic code and tackle genetic diseases more effectively. Known as genetic scissors, CRISPR identifies a DNA ...
If the first CRISPR decade was marked by a mad dash to evolve, engineer, and mine the bacterial universe for more and better genome-editing enzymes, so far the second seems to be all about three words ...
CRISPR Therapeutics has begun realizing sales on Casgevy, its first therapy and a joint venture with Vertex Pharmaceuticals. The company has plenty of cash to fund research and development for the ...
Last year, a ten-month-old baby in the US was the first person in the world to have their rare genetic disease effectively cured through the use of CRISPR gene editing technology. But the rollout of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results